Details for New Drug Application (NDA): 208051
✉ Email this page to a colleague
NDA 208051 describes NERLYNX, which is a drug marketed by Puma Biotech and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the NERLYNX profile page.
The generic ingredient in NERLYNX is neratinib maleate. One supplier is listed for this compound. Additional details are available on the neratinib maleate profile page.
The generic ingredient in NERLYNX is neratinib maleate. One supplier is listed for this compound. Additional details are available on the neratinib maleate profile page.
Summary for 208051
| Tradename: | NERLYNX |
| Applicant: | Puma Biotech |
| Ingredient: | neratinib maleate |
| Patents: | 10 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208051
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 208051
| Mechanism of Action | Kinase Inhibitors P-Glycoprotein Inhibitors |
Suppliers and Packaging for NDA: 208051
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NERLYNX | neratinib maleate | TABLET;ORAL | 208051 | NDA | Puma Biotechnology, Inc. | 70437-240 | 70437-240-18 | 1 BOTTLE in 1 BOX (70437-240-18) / 180 TABLET in 1 BOTTLE |
| NERLYNX | neratinib maleate | TABLET;ORAL | 208051 | NDA | Puma Biotechnology, Inc. | 70437-240 | 70437-240-26 | 1 BOTTLE in 1 BOX (70437-240-26) / 126 TABLET in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 40MG BASE | ||||
| Approval Date: | Jul 17, 2017 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jun 28, 2024 | ||||||||
| Regulatory Exclusivity Use: | NEW DOSING REGIMEN FOR THE PREVENTION AND MANAGEMENT OF NERATINIB‐ASSOCIATED DIARRHEA | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Oct 15, 2028 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Oct 15, 2028 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY | ||||||||
Expired US Patents for NDA 208051
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
